DARE - Daré Bioscience Inc. (DARE) Q1 2024 Earnings Call Transcript
2024-05-14 18:30:25 ET
Daré Bioscience, Inc. (DARE)
Q1 2024 Earnings Call Transcript
May 14, 2024 04:30 PM ET
Company Participants
Sabrina Martucci Johnson - President and CEO
MarDee Haring-Layton - Chief Accounting Officer
Conference Call Participants
Douglas Tsao - H.C. Wainright
Kemp Dolliver - Brookline Capital Markets
Catherine Novack - Jones Research
Presentation
Operator
Welcome to the conference call hosted by Daré Bioscience to review the company's First Quarter Financial Results and to provide the General Business Update. This call is being recorded. My name is Alex and I will be your operator for today.
With us today from Daré are Sabrina Martucci Johnson, President and Chief Executive Officer; and MarDee Haring-Layton, Chief Accounting Officer. Ms. Johnson, please proceed.
Sabrina Martucci Johnson
Thank you. Good afternoon and welcome to the Daré Bioscience Financial Results and Business Update Call for the quarter ended March 31, 2024. Today, we'll review our first quarter results and discuss developments and expectations from our pipeline and portfolio.
I would like to remind you that today's discussion will include forward-looking statements within the meaning of the Federal Securities Laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements made during this call that are not statements of historical fact should be considered forward-looking statements. Actual results or events could differ materially from those anticipated or implied by these statements due to known and unknown risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements are qualified in their entirety by the cautionary statements in the company's SEC filings, including our Form 10-Q for the quarter-end of March 31, 2024, which was filed today....
Daré Bioscience, Inc. (DARE) Q1 2024 Earnings Call Transcript